Methodological aspects and clinical results of an assay for thyroid-stimulating antibodies: correlation with thyrotropin binding-inhibiting antibodies
- PMID: 6144692
- DOI: 10.1210/jcem-58-6-980
Methodological aspects and clinical results of an assay for thyroid-stimulating antibodies: correlation with thyrotropin binding-inhibiting antibodies
Abstract
Several methodological aspects concerning the measurement of thyroid-stimulating antibodies (TSAb) were examined using a 5000-g particulate fraction from human thyroid tissue. TSH displayed maximal stimulation at 32 C. An ATP-regenerating system had no influence at ATP concentrations greater than 0.67 mM. Theophylline did not influence cAMP concentrations in the incubation medium after stimulation with increasing dosages of TSH, suggesting the absence of active phosphodiesterases in the membrane preparations. Sera dialyzed against Tris-HCl were as suitable as immunoglobulin G preparations for determination of TSAb. One hundred and nineteen patients with ophthalmic Graves' disease, 42 of whom were hyperthyroid at the time of study, were investigated for TSH binding-inhibiting antibodies ( TBIAb ) and TSAb. In 76% of these patients, concordance between the presence and absence of both activities was found independent of whether they were untreated, treated, or in remission. When gradations of potency in the two systems were compared, linear regression revealed a correlation coefficient of 0.59. The coefficient correlation increased when TBIAb and TSAb were each determined in a single assay using identical thyroid membrane preparations. In four other patients, both TSAb and TBIAb were measured repeatedly during the course of the disease. In three patients, both activities were parallel, whereas in one patient, dissociation of the two activities was found. The data suggest the presence of antibodies with varying stimulating and binding-inhibiting properties. However, in hyperthyroidism of Graves' disease, both activities usually were present in similar quantities.
Similar articles
-
Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.Thyroid. 1999 Aug;9(8):769-73. doi: 10.1089/thy.1999.9.769. Thyroid. 1999. PMID: 10482368 Clinical Trial.
-
Heterogeneity of Graves' immunoglobulin G: comparison of thyrotropin receptor antibodies in serum and in culture supernatants of lymphocytes transformed by Epstein-Barr virus infection.J Clin Endocrinol Metab. 1987 Feb;64(2):215-8. doi: 10.1210/jcem-64-2-215. J Clin Endocrinol Metab. 1987. PMID: 2878934
-
Adenylate cyclase activity and the accumulation and release of adenosine 3',5'-monophosphate in normal human thyroid tissue slice preparations: responses to thyrotropin and thyroid-stimulating antibodies.J Clin Endocrinol Metab. 1981 Aug;53(2):246-53. doi: 10.1210/jcem-53-2-246. J Clin Endocrinol Metab. 1981. PMID: 6114107
-
Detection of tsh binding inhibiting antibodies (TBI-ab) and thyroid adenylate cyclase stimulating antibodies (TS-ab) in sera of patients with Graves' disease.Boll Soc Ital Biol Sper. 1985 Jan 30;61(1):55-60. Boll Soc Ital Biol Sper. 1985. PMID: 3838478
-
Immunology of the thyrotropin receptor.Immunol Commun. 1976;5(5):345-60. doi: 10.3109/08820137609033853. Immunol Commun. 1976. PMID: 61168 Review.
Cited by
-
The thyrotropin receptor and its role in Graves' disease.J Endocrinol Invest. 1985 Apr;8(2):175-82. doi: 10.1007/BF03350678. J Endocrinol Invest. 1985. PMID: 2993404 Review. No abstract available.
-
Thyroid stimulating antibodies in rheumatoid arthritis: an in vitro phenomenon.J Endocrinol Invest. 1987 Oct;10(5):495-8. doi: 10.1007/BF03348178. J Endocrinol Invest. 1987. PMID: 2892878
-
Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.Klin Wochenschr. 1985 Dec 16;63(24):1247-52. doi: 10.1007/BF01738449. Klin Wochenschr. 1985. PMID: 2868149
-
Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.J Endocrinol Invest. 1986 Feb;9(1):37-42. doi: 10.1007/BF03348060. J Endocrinol Invest. 1986. PMID: 2422245
-
Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey.J Endocrinol Invest. 1996 Nov;19(10):682-6. doi: 10.1007/BF03349039. J Endocrinol Invest. 1996. PMID: 9007700
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources